BMY - Infinity loses a fifth ahead of key data readout for eganelisib

Infinity Pharmaceuticals ([[INFI]] -21.5%) is paring the ~36.4% gain it made yesterday with analysts attributing the drop to a summary of eganelisib data to be presented by the company at a virtual medical conference on Thursday.In January, Infinity announced that an Independent Data Monitoring Committee determined that there was a favorable risk/benefit for patients after eganelisib dose was cut from 40mg QD to 30mg QD.The dose reduction was in response to reversible liver enzyme elevations seen following the first scheduled IDMC meeting for MARIO-275. At the time, the company said it was planning a new registration-enabling study and would not re-open enrollment in MARIO-275.MARIO-275 is a Phase 2 randomized, placebo-controlled trial to evaluate the benefit of adding eganelisib to nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced, metastatic urothelial cancer (mUC) over nivolumab monotherapy.According to Jones Trading, which rates the stock a buy, the abstract released Monday night showed liver toxicity in

For further details see:

Infinity loses a fifth ahead of key data readout for eganelisib